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Purpose: The Genous™ stent (GS) is designed to accelerate endothelization, which is potentially useful in the
pro-thrombotic environment of ST-elevation acute myocardial infarction (STEMI). We aimed to evaluate the
safety and effectiveness of the GS in the ﬁrst year following primary percutaneous coronary intervention (PCI)
and to compare our results with the few previously published studies.
Methods andMaterials: All patients admitted to a single center due to STEMI that underwent primary PCI using
exclusively GS, betweenMay 2006 and January 2012, were enrolled. The primary study endpoints were major
adverse cardiac events (MACEs), deﬁned as the composite of cardiac death, acute myocardial infarction and
target vessel revascularization, at one and 12 months.
Results: In the cohort of 109 patients (73.4% male, 59 ±12 years), 24.8% were diabetic. PCI was performed in
116 lesionswith angiographic success in 99.1%, using 148GSwithmedian diameter of 3.00 mm(2.50–4.00) and
median length of 15 mm (9–33). Cumulative MACEs were 2.8% at one month and 6.4% at 12 months. Three
stent thromboses (2.8%), all subacute, and one stent restenosis (0.9%) occurred. These accounted for the four
target vessel revascularizations (3.7%). At 12 months, 33.9% of patients were not on dual antiplatelet therapy.
Conclusions: GS was safe and effective in the ﬁrst year following primary PCI in STEMI, with an apparently safer
proﬁle comparing with the previously published data.
Summary: We report the safety and effectiveness of the Genous™ stent (GS) in the ﬁrst year following primary
percutaneous coronary intervention in ST-elevation acutemyocardial infarction. A comprehensive review of the
few studies that have been published on this subject was included and some suggest a less safe proﬁle of the GS.
Our results and the critical review included may add information and reinforce the safety and effectiveness of
the GS in ST-elevation in acute myocardial infarction.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The Genous™ bio-engineered R stent™ (GS) (OrbusNeich, Fort
Lauderdale, Florida), is covered by monoclonal CD34+ antibodies that
selectively capture the circulating endothelial progenitor cells, which
accelerate the healing of the stented lesion [1,2]. Usage of the GS
speciﬁcally in ST-elevation acute myocardial infarction (STEMI) may
offer great beneﬁt in a highly pro-thrombotic environment, poten-
tially reducing stent thrombosis [3,4]. On the other hand, patientenous™ stent; MACE, major
rvention; STEMI, ST-elevation
cardial infarction; TLR, target
tion.
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myocardial infarction is suboptimal [5] and the GS could minimize
the consequences of early DAPT discontinuation [6]. Few studies have
been published on the safety and effectiveness of the GS use
exclusively in STEMI patients [7–13]. Different results have been
reported and a less safe proﬁle of the GS has been suggested in some
of these studies [7,8,13].
We aimed to evaluate the safety and effectiveness of the GS in the
ﬁrst year following primary percutaneous coronary intervention (PCI)
in STEMI. We also reviewed the clinical results of the published
studies on the GS usage that only included STEMI patients.
2. Methods
2.1. Patients and data collection
We conducted a cohort study of all STEMI patients admitted to our
center treated with primary PCI using exclusively GS, between Mayess of the Genous™ endothelial progenitor cell-capture stent in the
13), http://dx.doi.org/10.1016/j.carrev.2013.09.004
Table 1
Demographic and clinical data.
N = 109 %
Male 80 73.4
Hypertension 61 56.0
Dyslipidemia 58 53.2
Smoking history 58 53.2
Diabetes mellitus 27 24.8
Obesity 19 17.4
Previous acute myocardial infarction 7 6.4
Previous percutaneous coronary intervention 3 2.8
Previous coronary artery bypass grafting 0 0.0
Pre-discharge depressed left ventricular ejection fraction (b55%) 51 46.8
2 T. Pereira-da-Silva et al. / Cardiovascular Revascularization Medicine xxx (2013) xxx–xxx2006 and January 2012. The study protocol was approved by the
hospital ethics committee and all patients signed informed consent
forms before primary PCI.
In our center, the STEMI patients with barriers to prolonged dual
antiplatelet therapy (DAPT) were selected to receive a Genous™ stent
(GS) during the study period. The barriers included low patient
adherence to the treatment regimen, the need to interrupt antiplate-
let therapy due to non-cardiac invasive procedures or an increased
hemorrhagic risk (mainly due to concomitant need for oral antic-
oagulation or recent bleeding). We analyzed the STEMI patients that
received exclusively the GS.
Based on the clinical ﬁles, the following data were recorded:
demographic and clinical data, including cardiovascular risk factors,
previous cardiovascular events and other comorbidities; angio-
graphic and PCI procedural data; and inhospital clinical and
angiographic complications.
A clinical follow-up at one month and 12 months after discharge
was carried out based on clinic visits or phone enquiry, and the
following data were accounted for and veriﬁed by hospital records:
death, acute myocardial infarction, target vessel revascularization
(TVR), target lesion revascularization (TLR), clinical stent restenosis,
stent thrombosis, angina or anginal equivalent and DAPT
discontinuation.
Usage of a stent other than Genous™, rescue PCI and PCI
performed after the ﬁrst 12 h of the beginning of the symptoms
were the exclusion criteria.Table 2
Angiographic data.
N = 109 %
Multivessel disease 37 33.9
Lesions treated per patient
1 102 93.6
N1 7 6.4
Intervened lesion N = 116 %
Left anterior descending artery 49 42.2
Right coronary artery 47 40.5
Circumﬂex artery 19 16.4
Left main artery 1 0.9
Lesion risk proﬁle N = 116 %
Lesion type B2/C 78 67.2
Long lesion 34 29.3
Bifurcation lesion 13 11.2
Calciﬁed lesion 4 3.4
Thrombotic lesion 69 59.5
Previous stenting (another stent) 2 1.72.2. Endpoints
The primary study endpoints were major adverse cardiac events
(MACEs), deﬁned as the composite of cardiac death, acute myocardial
infarction and target vessel revascularization, at one and 12 months.
The incidence of stent thrombosis and clinical stent restenosis was
also assessed.
2.3. Deﬁnitions
All deaths were considered a cardiac death unless otherwise
documented. Acute myocardial infarction was deﬁned according to
Academic Research Consortium deﬁnition [14] as elevation of cardiac
enzymes 3 times the upper limit of normal. TVR was deﬁned as repeat
revascularization of the previously treated vessel, and TLR as repeat
revascularization within 5 mm to stent edges (in-segment). Clinical
stent restenosis was deﬁned as the presence of angina or anginal
equivalent, associated with N50% stenosis in the segment covered by
the stent or the adjacent 5 mm. Stent thrombosis was classiﬁed
according to Academic Research Consortium deﬁnitions [14] in which
deﬁnite stent thrombosis is deﬁned as angiographic or pathologic
conﬁrmation of acute stent thrombosis in patients with acute
coronary syndromes; and probable stent thrombosis as any unex-
plained death in the 30 days following stent implantation or as target
vessel myocardial infarction without angiographic conﬁrmation of
stent thrombosis or other identiﬁed culprit lesion. Stent thrombosis
was classiﬁed as acute (ﬁrst 24 h), subacute (between 24 h and
30 days) and late (after 30 days). Angiographic success was deﬁned
as residual stenosis of less than 10% and thrombolysis in myocardial
infarction (TIMI) ﬂow score 3.
2.4. Review of the published data
We searched the studies in full version indexed in the Pubmed®,
between January 2005 (GS ﬁrst-in-man [15]) andMay 2013, using the
keywords endothelial progenitor cell, Genous™ stent, myocardial
infarction, percutaneous coronary intervention, and stent. Of the
studies reporting GS usage, only those that enrolled exclusively STEMIPlease cite this article as: Pereira-da-Silva T, et al, Safety and effectiven
ﬁrst year following ST-elevation acute m..., Cardiovasc Revasc Med (20patients were analyzed. Time of follow-up, the number of GS used, the
number of patients included, intended DAPT duration, MACE, cardiac
death, acute myocardial infarction, TVR, TLR, stent restenosis and
stent thrombosis were analyzed.2.5. Statistical analysis
Data were analyzed using the SPSS version 17.0 statistical
software. Discrete data are presented as frequencies and percentages,
whereas continuous variables are presented as means and SD or as
medians and range, when appropriate.3. Results
Nine hundred and seventy (970) STEMI patients were treated with
primary PCI in our center during the study period. Of these, 115
patients received a GS since they had barriers to prolonged DAPT, but
six were excluded since they received another type of stent in
addition to the GS. In our cohort of 109 patients, 80 (73.4%) were male
and the mean age was 59 ±12 years. Demographic and clinical data
are presented in Table 1. One quarter of the patients had diabetes
mellitus on medication.
Angiographic data are presented in Table 2. In 102 (93.6%) patients
only the culprit artery was treated and PCI was performed in 116
lesions. Of the intervened lesions, 49 (42.2%) were located in the left
anterior descending artery, 78 (67.2%) were type B2/C and the mean
stenosis was 95.6% ± 12.0%.
Procedural data are presented in Table 3. Angiographic success
was achieved in 115 (99.1%) PCIs. One hundred and forty eight GSs
were used with a median diameter of 3.00 mm (2.50–4.00 mm) and a
median length of 15 mm (9–33 mm). Anticoagulant and antiplateletess of the Genous™ endothelial progenitor cell-capture stent in the
13), http://dx.doi.org/10.1016/j.carrev.2013.09.004
Table 3
Procedural data.
Pre-
intervention
Post-
intervention
TIMI ﬂow score N = 116 (%) N = 116 (%)
0 68 (58.6) 0 (0.0)
1 10 (8.6) 0 (0.0)
2 5 (4.3) 1 (0.9)
3 33 (28.4) 115 (99.1)
N = 109 %
Number of stents per patient
1 75 68.8
N1 34 31.2
Glycoprotein IIb/IIIa inhibitors (abciximab or
tiroﬁban)
76 69.7
Thrombus aspiration 18 16.5
TIMI: thrombolysis in myocardial infarction.
3T. Pereira-da-Silva et al. / Cardiovascular Revascularization Medicine xxx (2013) xxx–xxxtherapy followed the standard practices [16] and intended DAPT
duration was 12 months, for all patients.
3.1. Follow-up
Follow-up was achieved in all of the patients in this cohort. The
cumulative event rates during hospitalization, at one month and
12 months after PCI are presented in Table 4. Themean DAPT duration
was 9.8 ± 3.5 months and the clinical events that occurred under
DAPT and after DAPT discontinuation are presented in Table 4.
During hospitalization, one stent thrombosis occurred 48 h after
PCI (subacute). Thrombus aspiration and balloon angioplasty were
performed with success and the patient survived the recurrent
myocardial infarction. There was no acute stent thrombosis.
Between discharge and one month follow-up, two reinfarctions
were documented, both due to subacute GS thrombosis. One
occurred 11 days after PCI and the patient was on 100 mg aspirin
plus 75 mg clopidogrel per day, despite weighting 141 kg. The other
stent thrombosis occurred 21 days after PCI and the patient had
discontinued DAPT since discharge, against medical advice. In both
patients PCI was performed with success and both survived. At the
end of the ﬁrst month (107 patients alive), 6.5% of patients were not
on DAPT.Table 4
Cumulative events at inhospital, 1 month, 12 months, under DAPT and after DAPT disconti
Period of follow-up Inhospital 1 month
N % N %
Patients 109 100 109 100
MACE 1 0.9 3 2.8
Death 2 1.8 2 1.8
Cardiac 0 0.0 0 0.0
Non-cardiac 2 1.8 2 1.8
Acute myocardial infarction 1 0.9 3 2.8
TVR/TLRa 1 0.9 3 2.8
CABG 0 0.0 0 0.0
PCI 1 0.9 3 2.8
Clinical stent restenosis 0 0.0 0 0.0
Stent thrombosis 1 0.9 3 2.8
Deﬁnite 1 0.9 3 2.8
Probable 0 0.0 0 0.0
Acute 0 0.0 0 0.0
Subacute 1 0.9 3 2.8
Late 0 0.0 0 0.0
CABG: coronary artery bypass grafting; DAPT: dual antiplatelet therapy; MACE: major
revascularization; TVR: target vessel revascularization.
a All the TVRs were TLRs.
Please cite this article as: Pereira-da-Silva T, et al, Safety and effectiven
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occurred: an acutely decompensated heart failure (month 6), a
reinfarction unrelated to the culprit lesion at the index event
(month 7), and a sudden unexplained death (month 7). There was
one stent restenosis presenting as an acute coronary syndrome
seven months after PCI. Disease progression to triple vessel disease
(including restenosis of the GS) was documented and surgical
revascularization was performed. No late stent thrombosis was
documented. At the end of 12 months (99 patients alive), 33.9% of
patients were not on DAPT.
4. Discussion
Usage of the GS speciﬁcally in STEMI may be an important
alternative since it may reduce stent thrombosis in a highly pro-
thrombotic environment [3,4]. It may also minimize the conse-
quences of early DAPT discontinuation [6]. STEMI patients with
barriers to DAPT were selected to receive the GS in our center
and this study evaluated the 12-month safety and effectiveness
of the GS following primary PCI in a cohort of 109 patients. The
GS had a good performance, probably related to the rapid
endothelization [17]. MACE, cardiac death, TVR/TLR, clinical stent
restenosis and stent thrombosis rates were low despite frequent
early DAPT discontinuation.
About one third of patients were not on DAPT at 12 months
following the acute coronary syndrome. In addition, some patients
may have transiently interrupted DAPT for non-cardiac invasive
procedures, thus increasing the thrombotic risk. The use of other type
of stents might have been associated with a higher stent thrombosis
rate in these patients [18].
4.1. Review of the published data
Table 5 summarizes the clinical results of the few published
studies that included patients treated with the GS exclusively in
STEMI and includes our results as well. Data are expressed as
cumulative events at the end of the follow-up period and are
presented according to the deﬁnitions used in our study. The studies
by Bystroň et al [7]. and Co et al [9]. are exceptions, since
cardiovascular death (including stroke) is presented instead of cardiacnuation.
12 months Under DAPT
9.8 ±
3.5 months
After DAPT
discontinuation
2.2 ±
3.5 months
N % N % N %
109 100 72 66.1 37 33.9
7 6.4 4 5.6 3 8.1
10 9.2 7 9.7 3 8.1
3 2.8 2 2.8 1 2.7
7 6.4 5 6.9 2 5.4
4 3.7 3 4.2 1 2.7
4 3.7 4 5.6 0 0.0
1 0.9 1 1.4 0 0.0
3 2.8 3 4.2 0 0.0
1 0.9 0 0.0 0 0.0
3 2.8 2 2.8 1 2.7
3 2.8 2 2.8 1 2.7
0 0.0 0 0.0 0 0.0
0 0.0 0 0.0 0 0.0
3 2.8 2 2.8 1 2.7
0 0.0 0 0.0 0 0.0
adverse cardiac event; PCI: percutaneous coronary intervention; TLR: target lesion
ess of the Genous™ endothelial progenitor cell-capture stent in the
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Table 5
Studies on GS use exclusively in STEMI (cumulative events at the end of follow-up).
Bystroň M [7]. Scacciatella P [8]. Co M [9]. Present study Lee Y [10]. Santas-Alvarez [11] Chong E [12]. Low A [13].
FUP (months) 6 6 12 12 12 18 (mean) 24 34 (mean)
# GS 60 74 129 148 357 177 106 104
# Patients 50 50 120 109 321 139 95 95
Intended DAPT (months) 1 1 1 12 1 12 1 1
MACE (%) 24.0 18.0 9.2 6.4 12.2 – 13.7 15.8
Cardiovascular deatha/cardiac deathb (%) 4.0a 2.0b 3.3a 2.8b 5.9b 2.9b 9.5b 0.0b
Acute myocardial infarction (%) – 4.0 2.5 3.7 2.2 – 1.1 2.1
TLRc/TVRd (%) 14.0c 10.0c/
12.0d
5.8c,d 3.7c,d 4.1c/
4.4d
3.8c/
5.8d
4.2d –
SR ± symptomse/clinical SRf (%) 18.0e – 4.2f 0.9f – 5.0f – 28.4e
(8 mo)
ST (%) 6.0 0 1.7 2.8 0.9 1.4 1.1 0.0
Acute ST (%) 0.0 0 0.8 0.0 0.3 0.7 (inhospital) 1.1 0.0
Subacute ST (%) 2.0 0 0.8 2.8 0.6 0 0.0
Late ST (%) 4.0 0 0.0 0.0 0.0 0.7 0 0.0
DAPT: dual antiplatelet therapy; FUP: follow-up period; GS: Genous™ stent; MACE: major adverse cardiac events; SR: stent restenosis; ST: stent thrombosis; TLR: target lesion
revascularization; TVR: target vessel revascularization. Superscript a to f – outcomes considered in the original studies.
4 T. Pereira-da-Silva et al. / Cardiovascular Revascularization Medicine xxx (2013) xxx–xxxdeath and MACE includes cardiovascular death instead of cardiac
death. In addition, for the study by Bystroň et al [7],. TLR is presented
instead of TVR and MACE includes TLR instead of TVR. Of note, some
studies [9,10,12,13] were conducted in the same hospitals in
coincident periods, thus some patients may have been included in
different studies.
Some studies suggest that the GS might not be safe in STEMI
patients, as the rates of clinical complications were high, particularly
regarding MACE [7,8,13]. Methodological differences may account for
some of these results. The studies by Bystroň et al [7]. and Low et al
[13]. reported high rates of stent restenosis. Only on these studies, an
angiographic follow-up was performed, which may have increased
the detection of angiographically signiﬁcant but asymptomatic stent
restenosis, thus increasing repeat revascularization and MACE rates.
In the study by Scacciatella et al [8]. a single-photon emission
computed tomography was routinely performed at 6-month follow-
up (results not available) which may have increased the detection of
asymptomatic stent restenosis and also increased the rates of TVR and
MACE. In addition, the 34% multivessel PCI rate was high, which may
have added to the TVR rate. The study by Bystroň et al [7]. reported a
higher rate of stent thrombosis (6.0%) in comparison to any of the
other studies, where stent thrombosis ranged from 0.0% to 2.8% (in
our cohort), and the results of Bystroň et al. may be an outlier. Finally,
the studies by Bystroň et al [7]. and Scacciatella et al [8]. analyzed only
small samples (50 patients).
Although the rates of the events cannot be directly compared
between the different studies due to methodological differences, in
our cohort the GS seemed to show a safer proﬁle in comparison with
most studies — the rates of MACE, death, TVR/TLR and clinical stent
restenosis were numerically lower. Differences in clinical and
angiographic characteristics of the populations may account for
some of these differences, and possibly our cohort included lower
risk patients. The routine revaluation by coronary angiography or
single-photon emission computed tomography may also explain
higher event rates in some studies. In our study, the rate ofmultivessel
PCI was low (6.4%), while a multivessel PCI rate up to 34% has been
reported [8], which may have added to the TVR and MACE rates in the
latter. In addition, the intended DAPT duration was 12 months in our
study, and in most other studies it was 1 month; this may have
decreased the event rates in our cohort.
The stent thrombosis rate in our cohort was not lower than inmost
studies [8–13]. The three cases of deﬁnite stent thrombosis in our
study were subacute: the ﬁrst occurred early (48 h after PCI) without
any apparent stent abnormality in the following angiography; the
second was probably due to relative antiplatelet underdosing,
considering the overweight; the third was probably related to earlyPlease cite this article as: Pereira-da-Silva T, et al, Safety and effectiven
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[9,10,12] but none occurred in our patients. Late stent thrombosis, a
concern with drug eluting stents [19], was not documented in our
patients and only two of the analyzed studies have reported late
thrombosis with GS after STEMI [7,11] (Table 5).
4.2. Limitations
This study has the limitations of being a single center study,
including a small sample and reporting only clinical follow-up at one
year with no systematic angiographic revaluation. However, given the
lack of large studies on GS use in STEMI and the heterogeneity of data
in previous studies, our results and the review of the literature may
add information and reinforce the safety and effectiveness of the GS in
STEMI. Larger randomized studies are needed to conﬁrm safety and
efﬁcacy of the endothelial progenitor cell capturing technology.
5. Conclusions
The GS was safe and effective in the ﬁrst year following primary
PCI in STEMI patients, despite high rates of early DAPT discontinu-
ation. In our cohort the GS seemed to reveal a safer proﬁle in
comparisonwithmost previous studies. These results reinforce the GS
as a good option in STEMI patients.
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